Otonomy Inc OTIC Financial and Strategic SWOT Analysis Review [Report Updated: 12072017] Prices from USD $125

19:44 EDT 9 Aug 2017 | BioPortfolio Report Blog

Otonomy Inc OTIC Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description A detailed description of the company's operations and business divisions.
Corporate strategy Analyst's summarization of the company's business strategy.
SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.
Company history Progression of key events associated with the company.
Major products and services A list of major products, services and brands of the company.
Key competitors A list of key competitors to the company.
Key employees A list of the key executives of the company.
Executive biographies A brief summary of the executives' employment history.
Key operational heads A list of personnel heading key departments/functions.
Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
Key manufacturing facilities A list of key manufacturing facilities of the company.
Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.


Otonomy Inc Otonomy develops and markets treatments for diseases and disorders of the ear. The company's OTIPRIO is a FDA approved ciprofloxacin otic suspension indicated during tympanostomy tube placement surgery in pediatric patients. Its pipeline portfolio encompasses investigational candidates targeted at the treatment of patients with acute otitis media with tympanostomy tubes phase 2; cisplatininduced hearing loss phase 2, tinnitus phase 2, and Meniere's disease and other balance and hearing disorders phase 3. Otonomy is also conducting a preclinical program on sensorineural hearing loss including agerelated hearing loss. It employs its proprietary formulation technology that uses a thermosensitive gel and drug microparticles for enabling single dose treatment by a physician. Otonomy is headquartered in San Diego, California, the US.

Otonomy Inc Key Recent Developments

May 04,2017: Otonomy Reports First Quarter 2017 Financial Results and Provides Corporate Update
Mar 02,2017: Otonomy Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
Jan 09,2017: Otonomy Provides Corporate and Product Pipeline Update
Nov 30,2016: Otonomy appoints new chief scientific officer
Nov 03,2016: Otonomy Reports Third Quarter 2016 Financial Results and Provides Corporate Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Original Article: Otonomy Inc OTIC Financial and Strategic SWOT Analysis Review [Report Updated: 12072017] Prices from USD $125


More From BioPortfolio on "Otonomy Inc OTIC Financial and Strategic SWOT Analysis Review [Report Updated: 12072017] Prices from USD $125"

Quick Search

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...